한빛사논문
- 조회852
Soo-Ryum Yanga,1, Anne M. Schultheisb,1, Helena Yuc, Diana Mandelkera, Marc Ladanyia, Reinhard Büttnerb,*
aMemorial Sloan Kettering Cancer Center, Department of Pathology, United States
bUniversity of Cologne, Department of Pathology, Germany
cMemorial Sloan Kettering Cancer Center, Department of Medicine, United States
1These authors contributed equally to this work.
*Corresponding author.
Abstract
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there are highly effective targeted therapies against EGFR, ALK, ROS1, BRAF, TRK, RET, and MET. In addition, investigational therapies for KRAS, NRG1, and HER2 have shown promising results and may become standard-of-care in the near future. In parallel, immune-checkpoint therapy has emerged as an indispensable treatment modality, especially for patients lacking actionable oncogenic drivers. While PD-L1 expression has shown modest predictive utility, biomarkers for immune-checkpoint inhibition in NSCLC have remained elusive and represent an area of active investigation. Given the growing importance of biomarkers, optimal utilization of small tissue biopsies and alternative genotyping methods using circulating cell-free DNA have become increasingly integrated into clinical practice. In this review, we will summarize the current landscape and emerging trends in precision medicine for patients with advanced NSCLC with a special focus on predictive biomarker testing.
Keywords : Lung Cancer Diagnostics; Histological and Molecular Diagnostics; liquid biopsy; Tumor Mutational Burden; Resistance to EGFR-TKIs
논문정보
- Review Paper
- 2020년 07월 (BRIC 등록일 2020-08-13)
- 국외 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
